Device Week – April 4, 2016
This article was originally published in The Gray Sheet
In our latest European edition of the podcast, Clinica's Amanda Maxwell discusses where things stand with the move toward "scrutiny" mechanisms for high-risk devices; what the revised international ISO 13485 quality systems standard means for the EU; and regulatory questions around cranial stimulation devices with nonmedical claims.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.